Guardant Health (GH)
(Delayed Data from NSDQ)
$55.40 USD
+0.61 (1.11%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $56.09 +0.69 (1.25%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GH 55.40 +0.61(1.11%)
Will GH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GH
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
TMO Receives FDA Approval for Oncomine Dx Target Test
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Guardant Health (GH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
Other News for GH
NR7 appears for GH after 0.19% move
Guardant Health Director Makes Significant Stock Sale!
Insider Sell: Medina Hidalgo Sells 2,165 Shares of Guardant Health Inc (GH)
Guardant Health Expands Board, Appoints Alex Azar
The technical outlook for GH is unchanged after it falls 3.35% on September 12